Nuvation Bio
Robert DeVita has a diverse work experience in various roles and companies. Robert is currently working at Nuvation Bio as the Director of Corporate Development since April 2022. Prior to that, they worked at Citi as an Investment Banking Vice President from January 2022 to April 2022. Before that, they held roles such as Investment Banking Senior Associate and Investment Banking Senior Analyst at Citi from July 2018 to January 2022 and from July 2017 to July 2018, respectively. Robert also worked at Leerink Partners LLC as an Investment Banking Analyst from April 2014 to June 2017, and at EY as a Financial Services Consultant from June 2013 to April 2014. Robert gained experience as a Summer Intern at HGK Asset Management, Inc. in 2012 and 2011, and as a Winter Intern at Ladenburg Thalmann in 2011.
Robert DeVita attended Montclair Kimberley Academy from 2005 to 2009. From 2009 to 2013, they pursued a Bachelor of Science (B.S.) degree in Finance and Entrepreneurship at Lehigh University.
Nuvation Bio
2 followers
Nuvation Bio (NYSE: NUVB) is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio’s proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer.